Roche and Freenome struck a multiyear collaboration that gives Roche exclusive rights to develop and commercialize kit-based versions of Freenome's blood-based cancer screening tests outside the U.S., alongside a $75 million equity investment and potential milestone and royalty payments. Freenome retains U.S. rights and centralized testing options, Roche said in a joint announcement. The agreement includes access to Roche's plasma cohorts and technologies such as Elecsys, and contemplates exploring Roche's Axelios SBX sequencing platform for Freenome assays. Freenome noted the partnership is intended to accelerate international distribution and diagnostic kit development for early cancer detection.